Worm.com

AVG research reveals that cyber crime is now feared nearly three times more than burglary, five times more than assault

ORLANDO, Fla., June 9 /PRNewswire/ — AVG Technologies, a leading developer of Internet security software for consumers and SMEs, this week released the results of its own research study that showed U.S. citizens are more concerned about being the victims of cyber crime than burglary or assault.

Of the 1,000 PC users surveyed in March 2008 through market research company Ipsos, 57% felt that they will most likely be the victims of cyber crime with only 21% believing they will be victims of burglary.

  These results can be linked to two key behavioral trends:
  -- Very high use of the Internet for increasingly sensitive transactions:
     -- 74% of users shop online
     -- 67% of users bank online
     -- 63% of users pay bills online
  -- Low levels of protection with high concerns for cyber-related crime:
     -- 15% of users surveyed didn't know when security software was
        installed on their computers
     -- 91% of users agreed that cyber theft is certainly a concern

While 57% of users surveyed said they would most likely be the victims of cyber crime/theft, 73% felt confident that they were being protected by their Internet security provider.

"It’s clear that we still have a considerable amount of work to do to protect computer users against cybercrime," says AVG Technologies CEO J.R. Smith. "In the space of a few years, the nature of the threat has changed from a sport to professional criminal activity. The challenge for us now is to deliver security with a light touch that does not stifle innovation."

"Securing the Web, by its very nature, should be a collaborative undertaking. That’s why AVG’s threat research incorporates user input as a core component, fostering an environment in which users cooperate with researchers to ensure the protection of all."

AVG Technologies offers both free and commercial products to help home users and SMEs proactively protect their digital assets against unauthorized access or abuse. Home users can choose AVG Anti-Virus, AVG Anti-Virus plus Firewall, or AVG Internet Security, while business users can select networked versions of the Anti-Virus and Internet Security products as well as file- and email-server based Anti-Virus. AVG Free offers basic anti-virus, anti-spyware, and safe-searching protection for individual users. All products offer unobtrusive high-performance protection and ease of use, and are backed by global research laboratories providing frequent updates to ensure continuous protection.

About AVG Technologies

Founded in 1991 and headquartered in the Czech Republic, AVG is a leading international developer of Internet threat protection solutions for consumers, SMBs and small enterprises. AVG protects more than 70 million computer users around the world. The company has regional offices in North America and the United Kingdom, and employs some of the world’s leading experts in Internet security, specifically in the areas of threat research, analysis and detection. AVG’s award-winning products are distributed globally through resellers and over the Internet as well as via third parties through Software Developer’s Kits (SDK). Please visit http://www.avg.com/ for more information.

CONTACT: North America PR, Bryan Ferraro or Julie Parayno, +1-408-395-3600, both of Dovetail Public Relations for AVG Technologies

Web site: http://www.avg.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Picture this: you live on a sprawling estate in
the countryside. You have a security system that will alert you if any
unauthorized intruders make their way onto the property. The only problem
is, the “security system” is a squad of elderly gentlemen that shuffle
contentedly and slowly down the paths, through the gardens and across the
fields, taking a day or more to completely cover the estate. They will
radio the police if any trespassers are spotted, but given their speed, a
nimble criminal — or any number of them — could easily make their way in
and off with valuables before the old men are even aware of their presence,
and they’d probably be laughing the whole time.

Obviously you wouldn’t employ such a security system on your own property.
So why would you do so on your computer?

You’ve most likely spent due time and trouble to utilize the best
anti-virus and anti-spyware solutions that you could find to keep your
computer safe from harmful files. They could be likened to lithe,
black-suited security personnel patrolling your estate so you can sleep
soundly at night. But a common disease — file fragmentation — can turn
those agile protectors into the stooped old men from the first example. On
a disk with fragmented files, anti-virus and anti-spyware must take
substantial extra time to scan each and every fragment of each and every
file, causing scans to take many times longer than they should. Today,
fragmentation is very serious; files in hundreds or even thousands of
fragments are not at all uncommon.

Additionally, in today’s frantically active computing environments, there
are usually fixed times to schedule anti-virus and anti-spyware scans. If a
scan cannot complete within the fixed time, then it must either be aborted
or, worse, allowed to complete in a way that will slow down performance for
every user on the system.

The most effective handle on fragmentation in such circumstances is one
that is completely automatic, running invisibly in the background.
Utilizing only otherwise-idle resources, such a solution guarantees that
fragmentation is consistently addressed, and there is never a negative
performance hit from defragmentation. Scheduling is never required. The
fragmentation disease ceases to infect your applications, your file access
and your overall performance.

Don’t cripple the solutions you’ve employed to keep your computer safe.
Utilize fully automatic defragmentation and keep your security personnel
responsive, alert and fast-acting.

Contact:
Bruce Boyers Marketing Services
Email: Email Contact

Information provided by: Findarticles.com

SkyRecon Systems ( www.skyrecon.com ), the
premier provider of integrated, proactive endpoint security solutions,
today announced that FN Manufacturing, the maker of M16 rifles and small
arms for the U.S. military and law enforcement, has selected SkyRecon’s
StormShield for endpoint security on employee laptops.

FN Manufacturing first tried a variety of other measures, including
personal firewalls and anti-virus software, but found these did not provide
the necessary level of security, i.e. the same as that provided for desktop
systems located physically in the office. Presented with the dilemma of
balancing productivity with risk, FN Manufacturing had to find a solution
to secure their mobile workers .

“There is a lot of sensitive data on our laptops,” said Olivier
Vanderstraeten, FN Manufacturing’s network security systems manager.
“Besides the employee’s own personal information, there are often product
drawings and schematics. These are highly confidential.”

FN Manufacturing began researching better security options. Realizing that
anti-virus and personal firewalls were simply not enough to protect workers
off-site, whether working at the local coffee shop or while traveling, they
considered various vendors before selecting StormShield from SkyRecon
Systems.

“Now, we’re not so worried about where those laptops go and what they do
when they’re away from the office,” Vanderstraeten said. “StormShield gives
us the ability to set dynamic network-aware policies, such as prohibiting
connections to ad-hoc networks, so we know we can trust that users are
protected where they are most vulnerable — outside of our corporate
network.”

A recent TechWorld Awards finalist for Endpoint Security Product of
the Year, StormShield offers integrated system and data protection in a
single product. Relying on behaviors rather than signatures or heuristics
– approaches that are becoming more and more antiquated — StormShield
protects data where it is most at risk: on the endpoints. StormShield
provides integrated device
control , data
encryption , application
control , host-based intrusion
prevention ( HIPS ), system
firewall, wireless security ,
and Network Access Control ( NAC ). Its client-side agent also
provides zero-day protection without the need for signature or rule updates
– all using only a few megabytes of memory, a fraction of the size of
competing products on the market.

For more information regarding StormShield at FN Manufacturing, please
download the case study at
http://tinyurl.com/6725vh .

About SkyRecon Systems Inc.

Founded in 2003 in Paris and with US headquarters in San Jose, Calif.,
SkyRecon Systems is a provider of system and data security solutions for 200
enterprises in 40 countries. The company enjoys strategic partnerships with
Microsoft and Juniper in support of its engineering and sales efforts.
SkyRecon received the prestigious Red Herring 100 Award and has been named
“Entrepreneurial Security Company of the Year” by Frost & Sullivan. In 2007
it received a Readers Trust finalist award by SC Magazine. More information
on SkyRecon Systems can be found at www.skyrecon.com . SkyRecon Systems
Inc., 2033 Gateway Place, Suite 500, San Jose, CA 95110. Tel. (877) 239
3057.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Press Contact:
Sean Martin
CISSP
smartin@skyrecon.com
(949) 878-0592

Information provided by: Findarticles.com

AVI BioPharma, Inc. (NASDAQ: AVII) today
announced that Patrick Iversen, Ph.D., AVI’s Senior Vice President of
Strategic Alliances, will make the opening presentation of the
Pre-Conference Symposium to the 6th Annual Biodefense Vaccines &
Therapeutics Meeting to be held June 9-11, 2008 in Washington, D.C. The
Symposium is titled “Developments in Biodefense Vaccines & Therapeutics”
and Dr. Iversen’s presentation is “Multiple Phosphorodiamidate Morpholino
Oligomer Approaches to Developing Antiviral Therapeutics.”

This is an invitation-only meeting at which Dr. Iversen will principally
outline AVI’s progress on the development of its therapeutic drugs against
agents on the bioterrorism list, in particular Ebola, Marburg and Dengue
viruses.

In May of this year, the company announced that treatment of non-human
primates with either the antisense drug AVI-6002 or with AVI-6003, resulted
in a reproducible and high rate of survival in the face of an otherwise
lethal infection with Ebola or Marburg virus, respectively. Treatment of
mice with AVI compounds designed for the treatment of Dengue virus
infection have also resulted in reproducible and high rates of survival in
the face of otherwise lethal infections.

About Ebola Zaire, Marburg Musoke and Dengue Viruses

Ebola Zaire virus has been the most frequent cause of field outbreaks of
Ebola hemorrhagic fever and is endemic to sub-Saharan Africa. Ebola
hemorrhagic fever is a rare disease that can be fatal. Outbreaks first
occurred in 1976 in Zaire and in western Sudan. A recent outbreak occurred
in November of 2007 in Uganda ending in January of 2008. Infected
individuals develop high fevers, headache, muscle aches, vomiting, and
abdominal cramping. In fatal infections, bleeding is observed from the
nose, eyes, rectum and urethra. There is uniform mortality once
hemorrhagic signs appear as a result of exposure to the Ebola Zaire virus.

Marburg Musoke virus is the cause of Marburg hemorrhagic fever, a rare
disease that occurs naturally in sub-Saharan Africa. Marburg hemorrhagic
fever was first described in 1967 when outbreaks in Germany and the former
Yugoslavia were linked to monkeys imported from Uganda. The symptoms
include fever, diarrhea, vomiting, massive bleeding from multiple organs
and shock. Death generally occurs between 5 and 10 days after the onset of
symptoms.

Marburg and Ebola viruses are both members of the filoviridae viral family
and both are National Institutes of Allergy and Infectious Disease (NIAID)
priority A pathogens and bioterrorism suspect agents of interest to
Bioshield.

Dengue virus is a member of the flaviviridae viral family and is also an
NIAID priority A pathogen. Dengue virus is the cause of a complex of
clinical syndromes referred to as Dengue fever-dengue hemorrhagic fever.
Dengue is transmitted primarily by Aedes aegypti mosquitos, so the
infection is geographically located primarily in tropical climates of the
world. Dengue produces more human illness than any other
insect-transmitted viral disease. There are currently no commercially
available vaccines, chemoprophylactics, or effective therapeutics for
dengue.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NeuGene® antisense drugs
and alternative RNA splicing technology. AVI’s alternative RNA splicing
technology is initially being applied to potential treatments for Duchenne
muscular dystrophy. AVI’s NeuGene compounds are also designed to treat
cardiovascular restenosis. In addition to targeting specific genes in the
body, AVI’s antiviral program uses NeuGene antisense compounds to combat
disease by targeting single-stranded RNA viruses, including Marburg Musoke
and Ebola Zaire viruses. More information about AVI is available at
www.avibio.com .

“Safe Harbor” Statement under the Private Securities Litigation Reform Act
of 1995: The statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including, but not limited to, the results of research and
development efforts, the results of preclinical and clinical testing, the
effect of regulation by the FDA and other agencies, the impact of
competitive products, product development, commercialization and
technological difficulties, and other risks detailed in the company’s
Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Michael Hubbard
Email Contact
Director of Corporate Communications
(503) 227-0554

Information provided by: Findarticles.com

According to the Arizona Republic, on March 9, 10-year-old Paul Schalow and his family were taking a lunch break after riding ATVs in Arizona’s Tonto National Forest when a family member noticed a lion that was about to pounce on Paul.

Someone in the group yelled, and the lion attacked. It scratched Paul on the back and tried to bite him on the head. Paul managed to stay upright and not let the lion push him down to the ground. The lion paused in its attack and backed away a few steps. When it did, Paul’s uncle killed it with a pistol.

The mountain lion had rabies, and the family members who were exposed to the animal needed to get vaccinated for the virus. Though a representative of the Arizona Fish and Game Department said the uncle was right to shoot the lion, he scolded Paul’s grandfather for moving the lion after it was killed, exposing additional people to the rabies virus.

COPYRIGHT 2008 American Opinion Publishing, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

McAfee Spearheads Purpose-Built Security Solution for Virtual Environments

SANTA CLARA, Calif., June 9 /PRNewswire-FirstCall/ — McAfee, Inc. today announced it is extending its industry leading VirusScan(R) Enterprise product line to protect mission-critical enterprise applications. McAfee continuously researches new potential areas for attacks and will be the first to protect these new vectors. McAfee’s VirusScan family will include three new products: McAfee VirusScan Enterprise for Offline Virtual Images, McAfee VirusScan Enterprise for use with the SAP NetWeaver(R) platform, and McAfee VirusScan Enterprise for Storage.

"We’ve seen an evolution from mass-mailing viruses to more targeted attacks and threats targeting OS vulnerabilities moving to attacks against applications," said Rees Johnson, vice president of product management at McAfee. "McAfee is pioneering new technologies that help ensure customer’s mission-critical enterprise applications sitting in virtual environments, SAP solution-based environments and storage systems are protected. We see growth in attacks targeting systems that contain valuable data, and we will strive to provide the strongest possible protection for these systems."

Proven Security for Virtual Environments

Virtualization is being widely deployed in enterprise environments. Enhanced security is as important in a virtual environment as it is in a physical one. McAfee will be the first to introduce a purpose-built security solution for virtual environments. Industry research indicates that there are as many as five offline virtual images for every one online image. McAfee VirusScan Enterprise for Offline Virtual Images is specifically designed to secure offline virtual images that could become unpatched and out-of-date while they are inactive. The new product automatically updates and patches the offline virtual images periodically so they no longer pose a security risk to the virtual environment when they are activated.

"Customers look to VMware virtualization to help them deploy IT environments that are scalable, cost-effective, energy-efficient and secure," said Brian Byun, vice president of global partners and solutions at VMware. "We look forward to McAfee’s new solution that complements the robust security inherent in the VMware platform, and provides customers consistent protection for mission-critical applications running in VMware virtual machines."

"Virtualization-enabled data center consolidation delivers amazing cost-savings but requires careful review of existing security solutions as servers are virtualized," said Peter Christy, principal analyst at Internet Research Group. "McAfee is a market leader in terms of understanding these changing requirements and adapting their product offerings to provide effective security solutions in a virtualized environment."

Enterprise Class Security for use with SAP Solutions

McAfee will deliver an enterprise-class security solution that is available for use with SAP solutions. Many mission-critical functions within an organization, such as human resources, rely on SAP applications to gather and store external information. For example, candidate resumes are often submitted and entered via a company Web site directly into the SAP database. These resumes could be malicious and potentially compromise the SAP solution-based environment along with the sensitive mission-critical data. McAfee VirusScan Enterprise for use with SAP NetWeaver helps ensure business continuity by preventing malicious uploads to the SAP application.

Robust Security for the Storage Market

McAfee VirusScan Enterprise for Storage will provide proactive threat protection for viruses, worms, Trojans, spyware, botnets and rootkits. Infected files are scanned and cleaned before they ever reach the storage device. Real-time scanning for all types of files avoids propagation of infections to other parts of the environment.

"NetApp is pleased to see McAfee’s ongoing commitment to securing storage environments," said Patrick Rogers, vice president of Solutions Marketing at NetApp. "With this new product release, our joint customers can now have the peace of mind that comes with NetApp file services solutions secured by McAfee, a trusted partner in enterprise security."

Availability

Beta versions of all the solutions will be available in July with general availability in 2H 2008. For more information about McAfee’s solutions visit: http://www.mcafee.com/.

About McAfee, Inc.

McAfee, Inc., headquartered in Santa Clara, California, is the world’s largest dedicated security technology company. It delivers proactive and proven solutions and services that secure systems and networks around the world, allowing users to browse and shop the Web securely. With its unmatched security expertise and commitment to innovation, McAfee empowers home users, businesses, the public sector and service providers by enabling them to comply with regulations, protect data, prevent disruptions, identify vulnerabilities and continuously monitor and improve their security. http://www.mcafee.com/.

Information provided by: Findarticles.com

Results Discussed Last Week at Nanotechnology Conference in Boston

WEST HAVEN, Conn. — NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has posted photos on its website which show the rapid response to treatment using the Company’s nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC) (http://www.nanoviricides.com/action_small_EKC_2008-06-09.html).

The eyes treated with the best nanoviricide drug candidate showed virtual absence of inflammation and significant decrease in the redness of the conjunctiva, i.e. the area surrounding the cornea. The eyes treated with a negative control eye wash solution show the usual redness and inflammation caused by the disease. Substantial improvement occurred within only 2.5 days after treatment in this preliminary study. Further biological analyses are in progress.

"This may be the very first demonstration of a rapid and clear clinical response against adenoviral EKC," said Anil R. Diwan, PhD, President of the Company, adding, "The robustness of the nanoviricides technology is also now amply evident. We have demonstrated industry-leading efficacies in our very first experiments against widely varying viral diseases such as common influenza, H5N1 bird flu, rabies, Ebola, and now adenoviral EKC."

"We plan to evaluate this broad-spectrum eye-drop formulation against other viruses causing inflammation of the eye such as herpes simplex virus (HSV)," said Eugene Seymour, MD, MPH, CEO of the Company.

While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for these classes of eye disease is expected to be of the order of several billion dollars annually.

Dr. Seymour discussed these results and the broad-spectrum nature of nanoviricides drug candidates at the NSTI Nanotech 2008 conference in Boston last week.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company’s novel nanoviricide[TM] class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company’s research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management’s Discussion and Analysis" section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com